{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "Jarrod Sandow"}, {"accession": "MS:1000589", "name": "contact email", "value": "sandow@wehi.edu.au"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "WEHI"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Stephin J. Vervoort"}, {"accession": "MS:1000589", "name": "contact email", "value": "stephin.vervoort@petermac.org"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Peter MacCallum Cancer Centre, 305 Grattan St Melbourne VIC 3000"}]}], "datasetFiles": [{"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/06/PXD026539/P3853_jurkat.zip"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/06/PXD026539/jurkat_results.zip"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/06/PXD026539/P3853_OT1.zip"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/06/PXD026539/OT1_results.zip"}], "description": "Pharmacologicalinhibitors of cyclin dependent kinases 4 and 6 (CDK4/6) are an approvedtreatment forhormone receptor-positive breast cancer and are currently under evaluation across hundreds of clinical trials for other cancertypes. The clinical success of these inhibitorsis largely attributedto well-defined tumor-intrinsic   cytostatic   mechanisms,   while   their   emerging   role   as immunomodulatory  agents  is  lessunderstood. Usingintegrated  epigenomic,  transcriptomic  and proteomicanalyses,  we demonstrateda  novel  action  of  CDK4/6inhibitorsin promoting the phenotypic and functional acquisition of immunological T cell memory.Short-term priming with a CDK4/6inhibitorpromoted long-termendogenousanti-tumor T cell immunityin mice,  enhanced the persistence and therapeutic efficacy of chimeric antigen receptor (CAR)-T cells, and induced an RB-dependent T cell phenotype supportive offavorable responses to immune checkpoint blockade in melanoma patients.Together, thesemechanistic insights significantlybroaden the prospective utility of CDK4/6 inhibitors as clinical tools to boostanti-tumorT cell immunity.", "fullDatasetLinks": [{"accession": "MS:1002852", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/06/PXD026539"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD026539"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD026539"}], "instruments": [{"accession": "MS:1003005", "name": "timsTOF Pro"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "CDK4, t-cell, phosphoproteomics, CDK6"}], "modifications": [{"accession": "MOD:00696", "name": "phosphorylated residue"}], "publications": [{"terms": [{"accession": "MS:1002858", "name": "Dataset with its publication pending"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Mus musculus (Mouse)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "10090"}]}, {"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens (Human)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "CDK4/6 inhibition promotes anti-tumor immunity"}